کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3913853 1251453 2012 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Drospirenone- and levonorgestrel-containing oral contraceptives and the risk of gallbladder disease
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Drospirenone- and levonorgestrel-containing oral contraceptives and the risk of gallbladder disease
چکیده انگلیسی

BackgroundStudies have found an association between the use of estrogen-containing oral contraceptives (OCs) and the risk of gallbladder disease. This study evaluated this relation as well as the role of progestogen on the risk of gallbladder disease among users of drospirenone-containing OCs compared to users of levonorgestrel-containing OCs.Study DesignDatabase: The UK General Practice Research Database.We conducted a nested case–control analysis among women aged 14 to 60 years during 2001 through 2008 who had ever received drospirenone- or levonorgestrel-containing OCs. Cases were women with a first diagnosis of gallbladder disease during the study period. Women who received a study OC within 6 months of the index date were exposed. All other women were nonexposed. We matched two controls to each case on year of birth, index date, amount of recorded history and general practice attended.ResultsThe adjusted odds ratio for gallbladder disease comparing drospirenone and levonorgestrel OCs to nonexposure were 0.9 [95% confidence interval (CI) 0.7–1.1] and 1.0 (95% CI 0.9–1.1), respectively.ConclusionsThere is no evidence in these data that drospirenone- or levonorgestrel-containing OC use confers an increased risk of gallbladder disease compared to women not currently exposed to an OC. Nor is use of drospirenone OCs associated with a higher risk of gallbladder disease than use of levonorgestrel-containing OCs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Contraception - Volume 86, Issue 3, September 2012, Pages 220–223
نویسندگان
, ,